Page 7 - Precigen News Today

Precigen (NASDAQ:PGEN – Get Rating) is scheduled to issue its quarterly earnings data after the market closes on Monday, May 9th. Analysts expect the company to announce earnings of ($0.14) per share for the quarter. Precigen (NASDAQ:PGEN – Get Rating) last posted its earnings results on Tuesday, March 1st. The biotechnology company reported ($0.13) earnings […]

Wall Street analysts expect Precigen, Inc. (NYSE:PGEN – Get Rating) to report $20.90 million in sales for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Precigen’s earnings, with the lowest sales estimate coming in at $17.30 million and the highest estimate coming in at $24.50 million. Precigen posted sales of […]

Brokerages expect that Precigen, Inc. (NYSE:PGEN – Get Rating) will announce earnings of ($0.14) per share for the current quarter, Zacks reports. Two analysts have made estimates for Precigen’s earnings, with the lowest EPS estimate coming in at ($0.15) and the highest estimate coming in at ($0.13). Precigen posted earnings of ($0.11) per share in […]

/PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the...

PFG Advisors bought a new position in Precigen, Inc. (NASDAQ:PGEN – Get Rating) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 10,083 shares of the biotechnology company’s stock, valued at approximately $37,000. A number of other hedge funds also recently […]

Precigen, Inc. (NASDAQ:PGEN – Get Rating) saw a significant increase in short interest in the month of February. As of February 15th, there was short interest totalling 22,870,000 shares, an increase of 26.2% from the January 31st total of 18,120,000 shares. Based on an average trading volume of 1,680,000 shares, the days-to-cover ratio is presently […]

/PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the...

/PRNewswire/ -- Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of...

/PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the...

/PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the...